Bristol adds medicine to patent pool for AIDS drugs
LONDON (Reuters) - Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries.
The licensing deal will enable generic drug firms around the world to produce affordable versions of atazanavir, which Bristol sells under the brand name Reyataz, and to combine it with other medicines to make treatment easier.
The agreement announced on Thursday by the United Nations-backed Medicines Patent Pool is the first covering an HIV drug designed for use after patients develop resistance to initial treatments.
The World Health Organisation estimates there will be over 1 million people on such second-line treatments by 2016 and many more will need access to these therapies in the future.
(Reporting by Ben Hirschler; Editing by Greg Mahlich)
- First Ebola victim in Sierra Leone capital on the run
- Former WWE champ nabs suspected burglar in Arizona
- Apple iPhones allow extraction of deep personal data, researcher finds
- EU edges to economic sanctions on Russia but narrows scope |
- China's Guangdong province removes over 850 'naked officials' from their posts
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video